Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Tuesdays: X-article on biotech hot topics
Wednesdays: Podcast format of X-article
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Saturdays: Podcast format of Weekly News Update
Sundays: Building Biotech: Strategic Topics
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Welcome to the BowtiedBiotech Podcast! In today’s episode, we’ll dive into the groundbreaking moments that shaped 2024 in biopharma, from first FDA approvals by companies like Madrigal Pharmaceuticals and X4 Pharmaceuticals, to the rollercoaster of successes and setbacks in neuroscience drug development. We’ll explore how GLP-1s are transforming treatments beyond diabetes and obesity, discuss the persistent industry-wide layoffs, and highlight emerging trends like the growing demand for data-driven VC investments. Whether it’s life-changing breakthroughs, market dynamics, or the stories behind the science, we’ve got it all covered—so let’s get started!
📣🎙️ TODAY’S POCAST:
( 0:00 ) Welcome to Bowtied Biotech
( 0:28 ) 2024 Biopharma Highlights
( 1:12 ) Celebrating First-Time FDA Approvals
( 2:48 ) Neuroscience: Breakthroughs and Setbacks
( 4:42 ) GLP-1s: Expanding Beyond Obesity
( 6:32 ) Biopharma Layoffs and Restructuring
( 8:08 ) Data-Driven Biopharma Investment
( 9:55 ) FDA Leadership Changes
( 11:00 ) Future Opportunities in Biopharma
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post